PubMed Health⌕ Search

Biomedical subjects

A Basomba

Publications and source records attributed to A Basomba.

42 records · Page 3Linked to original sources
PubMedDate not supplied

Sensitivity to Parietaria officinalis and Parietaria judaica pollen allergens in a Spanish population.

To investigate the biological activity of P. judaica and P. officinalis allergen preparations, 36 Spanish patients were included in a biological standardization (BS) trial. For both species the concentration corresponding to 1000 biological units/ml (BU/ml) was found to be about 2 micrograms dry weight/ml (d.w./ml). The allergenic activity per microgram d.w. was about the same as reported for other important weed pollen extracts. The physico-chemical and immunological properties of the purified Parietaria judaica and Parietaria officinalis pollen allergen preparations used for biological standardization were investigated. The protein content was determined to 38% and 23% for P. judaica and P. officinalis respectively, while the carbohydrate content was 25% in both weed preparations. More than 40 antigens and at least 10 different allergens were detected by crossed immuno electrophoresis/crossed radio immunoelectrophoresis (CIE/CRIE) analyses. SDS-gPAGE followed by electroblotting showed important allergens between 10,000 and 75,000 d for both species. The crossreactivity as measured by skin prick test, RAST and CRIE was high.

Allergens↗
PubMedDate not supplied

[Investigation of the efficacy and tolerability of azelastine nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis].

The efficacy and safety of the nasally administered histamine H1 receptor blocking drug Azelastine was investigated in an open, multicenter, randomized comparative trial with Ebastine in seasonal allergic rhinitis. 110 patients in two parallel groups were treated for 14 days and efficacy was assessed by the physician using a rating scale measuring 10 nasal and ocular symptoms of seasonal rhinitis (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Tolerability was measured on the basis of reported adverse events. Both treatment groups had dramatic reductions in the physician's total symptom score following treatment (p < 0.0005). There was no significant difference between the two groups. Changes in individual rhinitis symptoms showed no differences between the two groups. During treatment, 19 patients had at least one adverse event, 13 in Azelastine group and 6 in Ebastine group; all were mild. The most frequent adverse events reported were somnolence (4 cases in Ebastine group) and a bitter taste (4 patients in the Azelastine group). In conclusion, the results of the study on 110 patients suggest that both Azelastine and Ebastine are effective treatments of the symptoms of seasonal allergic rhinitis. Both drugs were well tolerated.

Administration, Intranasal↗